Drug Trial Radar · NCT06065540
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,734
Actual
Start
Sep 27, 2023
Primary completion
Nov 19, 2025
Study completion Jan 6, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Oct 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
Conditions
- Type 2 Diabetes Mellitus
Interventions
CagrilintideDrug
Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached.
SemaglutideDrug
Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
Placebo cagrilintideDrug
Participants will receive placebo matched to cagrilintide subcutaneously.
Placebo semaglutideDrug
Participants will receive placebo matched to semaglutide subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to end of treatment (week 68)
Locations
405 sites in 32 countries. Site status is shown where the registry gives one.
Synexus Clin Res-Birmingham
Birmingham, Alabama
Univ of Alabama_Birmingham
Birmingham, Alabama
Cahaba Research
Pelham, Alabama
Velocity Clinical Research-Phoenix
Phoenix, Arizona
Synexus Rsch /Cnt Phnx Med C
Phoenix, Arizona
Arkansas Clinical Research
Little Rock, Arkansas
Velocity Clinical Res-Banning
Banning, California
Velocity Clin Res-Chula Vista
Chula Vista, California
John Muir Physicians Network
Concord, California
Headlands Research California, LLC
Escondido, California
Velocity Clin Res Gardena
Gardena, California
Velocity Clin Res San Diego
La Mesa, California
Loma Linda Univ Hlth Cr Endo
Loma Linda, California
Facey Medical Foundation
Mission Hills, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
Velocity Clin Res- San Bern
San Bernardino, California
Linda Vista Health Care Ctr
San Diego, California
Velocity Clin Res Santa Ana
Santa Ana, California
Premier Medical Center, Inc.
Toluca Lake, California
Velocity Clin Res - Panorama
Van Nuys, California
Optumcare Clinical Trials,LLC-Golden
Colorado Springs, Colorado
Northeast Research Institute
Jacksonville, Florida
Clinical Trial Services Corp
Miami, Florida
Bioclinical Research Alliance
Miami, Florida
New Horizon Research Center
Miami, Florida
South Broward Research LLC
Miramar, Florida
West Orange Endocrinology
Ocoee, Florida
Optimal Research Sites
Orange City, Florida
Advent Health-Res Inst
Orlando, Florida
AdventHealth Diab Inst
Orlando, Florida
Synexus Clin Res - Orlando
Orlando, Florida
Oviedo Medical Research, LLC
Oviedo, Florida
Hope Clin Res & Wellness
Conyers, Georgia
East Coast Institute for Res
Macon, Georgia
Urban Family Practice Assoc
Marietta, Georgia
Endocrine Research Solutions, Inc.
Roswell, Georgia
Endocrine Research Solutions
Roswell, Georgia
Pacific Diabetes & Endo Ctr
Honolulu, Hawaii
St. Luke's Health System
Boise, Idaho
Solaris Clinical Research
Meridian, Idaho
Showing 40 of 405 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.